Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results

Business Wire05:05

Delivers solid results in Q4; initiates FY25 guidance Fourth-quarter fiscal year 2024 Revenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023. GAAP net income...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486806845?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WFEj7pS9MljuY8tnJX.KzA--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/68fc5c5e50c34ca8d680f867c5edb3c1","is_english":true,"pubTime":"2024-11-26 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486806845","market":"us","top_or_hot":-1,"title":"Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results","media":"Business Wire","content":"<div>\n<p>Delivers solid results in Q4; initiates FY25 guidance\nFourth-quarter fiscal year 2024\n\nRevenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023.\nGAAP net income...</p>\n\n<a href=\"https://finance.yahoo.com/news/agilent-reports-fourth-quarter-fiscal-210500338.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/agilent-reports-fourth-quarter-fiscal-210500338.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Delivers solid results in Q4; initiates FY25 guidance\nFourth-quarter fiscal year 2024\n\nRevenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023.\nGAAP net income...</p>\n\n<a href=\"https://finance.yahoo.com/news/agilent-reports-fourth-quarter-fiscal-210500338.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"A","symbol_name":"安捷伦科技","start_time":0,"source_url":"https://finance.yahoo.com/news/agilent-reports-fourth-quarter-fiscal-210500338.html","article_id":"2486806845","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WFEj7pS9MljuY8tnJX.KzA--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/68fc5c5e50c34ca8d680f867c5edb3c1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486806845","pubTimestamp":1732568700,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Delivers solid results in Q4; initiates FY25 guidance. Revenue of $1.70 billion, up 0.8% reported and down 0.3% core from the fourth quarter of 2023.GAAP net income of $351 million; earnings per share  of $1.22, down 25% from the fourth quarter of 2023.Non-GAAP net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023.Fourth-quarter GAAP net income was $351 million, or $1.22 per share. This compares with $475 million, or $1.62 per share, in the fourth quarter of fiscal year 2023. Non-GAAP net income was $418 million, or $1.46 per share during the quarter, compared with $404 million or $1.38 per share during the fourth quarter a year ago.Agilent’s Life Sciences and Applied Markets Group  reported fourth-quarter revenue of $833 million, a decline of 1% reported and 1% core year-over-year. LSAG’s operating margin for the quarter was 28.0%. Full-year revenue of $3.22 billion declined 8% reported and 8% core over last year. LSAG’s operating margin for the year was 27","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"A":"安捷伦科技","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","CORE":"科尔.马克控股","LU1543694498.USD":"法巴水资源基金RH MD Dis","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","GRO":"Brazil Potash Corp.","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","BK4121":"生命科学工具和服务","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","PLM":"Polymet Mining","BK4588":"碎股","BK4168":"多种金属与采矿","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H"},"translate_title":"安捷伦公布2024财年第四季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLM":1,"CORE":1,"GRO":1,"A":1},"content_text":"Delivers solid results in Q4; initiates FY25 guidance\nFourth-quarter fiscal year 2024\n\nRevenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023.\nGAAP net income of $351 million; earnings per share (EPS) of $1.22, down 25% from the fourth quarter of 2023.\nNon-GAAP(2) net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023.\n\nFull fiscal year 2024\n\nRevenue of $6.51 billion, down 4.7% on a reported basis and down 4.7% core(1) year-over-year.\nGAAP net income of $1.289 billion; EPS of $4.43, up 6% year-over-year.\nNon-GAAP(2) net income of $1.539 billion; EPS of $5.29, down 3% year-over-year.\n\nFiscal year 2025 and first-quarter outlook\n\nFiscal year revenue is expected in the range of $6.790 billion to $6.870 billion, representing a range of up 4.3% to 5.5% on a reported basis and 2.5% to 3.5% core(1). Non-GAAP(3) earnings are expected in the range of $5.54 to $5.61 per share.\nFiscal first-quarter revenue guidance is expected in the range of $1.650 billion to $1.680 billion, a decline of 0.5% to an increase of 1.3% reported and a decline of 2.0% to 0.2% core(1). Non-GAAP(3) earnings are expected in the range of $1.25 to $1.28 per share.\n\nSANTA CLARA, Calif., November 25, 2024--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023.\nFourth-quarter GAAP net income was $351 million, or $1.22 per share. This compares with $475 million, or $1.62 per share, in the fourth quarter of fiscal year 2023. Non-GAAP(2) net income was $418 million, or $1.46 per share during the quarter, compared with $404 million or $1.38 per share during the fourth quarter a year ago.\n\"The Agilent team again executed well and delivered solid results in the fourth quarter as the markets continued to recover,\" said Agilent President and CEO Padraig McDonnell. \"Our new market-based, customer-first strategy combined with our transformation – which includes the new organizational structure announced today – will position us to capture even more growth opportunities as the market improves. I look forward to sharing more about these exciting developments during our Analyst and Investor Day in December.\"\nFinancial Highlights\nIn the first quarter of 2024, Agilent implemented certain changes to its segment reporting structure. Prior period segment information has been recast to reflect these changes. These changes have no impact on Agilent’s consolidated financial statements.\nLife Sciences and Applied Markets Group\nAgilent’s Life Sciences and Applied Markets Group (LSAG) reported fourth-quarter revenue of $833 million, a decline of 1% reported and 1% core(1) year-over-year. LSAG’s operating margin for the quarter was 28.0%. Full-year revenue of $3.22 billion declined 8% reported and 8% core(1) over last year. LSAG’s operating margin for the year was 27.3%.\nAgilent CrossLab Group\nThe Agilent CrossLab Group (ACG) reported fourth-quarter revenue of $426 million, an increase of 5% reported and 5% core(1) year-over-year. ACG’s operating margin for the quarter was 32.6%. Full-year revenue of $1.64 billion increased 5% reported and 5% core(1) over last year. ACG’s operating margin for the year was 31.9%.\nDiagnostics and Genomics Group\nThe Diagnostics and Genomics Group (DGG) reported fourth-quarter revenue of $442 million, a decrease of 1% reported and 3% core(1) year-over-year. DGG’s operating margin for the quarter was 21.2%. Full-year revenue of $1.65 billion declined 6% reported and 6% core(1) over last year. DGG’s operating margin for the year was 19.4%.\nFull Year 2025 and First-Quarter Outlook\nFull-year revenue outlook is expected in the range of $6.790 billion to $6.870 billion, representing a range of up 4.3% to 5.5% reported and 2.5% to 3.5% core(1). Non-GAAP(3) EPS is expected in the range of $5.54 to $5.61 per share.\nThe outlook for first-quarter revenue is expected to be in the range of $1.650 billion to $1.680 billion, a decline of 0.5% to an increase of 1.3% reported and a decline of 2.0% to 0.2% core(1). Non-GAAP(3) EPS is expected in the range of $1.25 to $1.28 per share.\nThe outlook is based on forecasted currency exchange rates.\nConference Call\nAgilent’s management will present additional details regarding the company’s fourth-quarter 2024 financial results on a conference call with investors today at 1:30 p.m. PT. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the \"Q4 2024 Agilent Technologies Inc. Earnings Conference Call\" link on the Agilent Investor Relations website. The replay of the call will remain on the company site for 90 days.\nOrganizational Structure Announcement\nAgilent today also announced a new organizational structure, an important step in the company’s transformation to become nimbler and more customer centric. Read the announcement. Agilent will share more information about the company’s evolved market-focused strategy and transformation at its Investor Day in New York City on Dec. 17, 2024. See details here.\nAbout Agilent Technologies\nAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.\nForward-Looking Statements\nThis news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s growth prospects, business, financial results, revenue, non-GAAP earnings guidance for Q1 and fiscal year 2025, and the effects of its new organizational structure, operational transformation and market-focused strategy. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its operational transformation, market-focused strategy and cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2024. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.\n(1) Core revenue growth excludes the impact of currency and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. Reconciliations between GAAP revenue and core revenue for Q4 fiscal year 2024 and full fiscal year 2024 are set forth on pages 6 and 7 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth rate as projected for Q1 fiscal year 2025 and full fiscal year 2025 excludes the impact of currency and acquisitions and divestitures within the past 12 months. Most of the excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided for the projection.\n(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of restructuring and other related costs, asset impairments, intangibles amortization, transformational initiatives, acquisition and integration costs and net (gain) loss on equity securities. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 4 of the attached tables along with additional information regarding the use of this non-GAAP measure.\n(3) Non-GAAP earnings per share as projected for Q1 fiscal year 2025 and full fiscal year 2025 exclude primarily the estimated impacts of non-cash intangibles amortization, transformational initiatives, and acquisition and integration costs. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. Most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $28 million per quarter.\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nCONDENSED CONSOLIDATED STATEMENT OF OPERATIONS\n\n\n(In millions, except per share data)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThree Months Ended\n\nYears Ended\n\n\n\n\nOctober 31,\n\nOctober 31,\n\n\n\n\n2024\n\n2023\n\n2024\n\n2023\n\n\n\n\n\n\n\n\n\n\n \n\n\nNet revenue\n\n$\n1,701\n\n\n$\n1,688\n\n\n$\n6,510\n\n\n$\n6,833\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nCosts and expenses:\n\n\n\n\n\n\n\n\n\n\nCost of products and services\n\n\n785\n\n\n\n773\n\n\n\n2,975\n\n\n\n3,368\n\n\n\nResearch and development\n\n\n111\n\n\n\n114\n\n\n\n479\n\n\n\n481\n\n\n\nSelling, general and administrative\n\n\n397\n\n\n\n393\n\n\n\n1,568\n\n\n\n1,634\n\n\n\nTotal costs and expenses\n\n\n1,293\n\n\n\n1,280\n\n\n\n5,022\n\n\n\n5,483\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nIncome from operations\n\n\n408\n\n\n\n408\n\n\n\n1,488\n\n\n\n1,350\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nInterest income\n\n\n24\n\n\n\n17\n\n\n\n80\n\n\n\n51\n\n\n\nInterest expense\n\n\n(32\n)\n\n\n(22\n)\n\n\n(96\n)\n\n\n(95\n)\n\n\nOther income (expense), net\n\n\n1\n\n\n\n17\n\n\n\n49\n\n\n\n33\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nIncome before taxes\n\n\n401\n\n\n\n420\n\n\n\n1,521\n\n\n\n1,339\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nProvision for (benefit from) income taxes\n\n\n50\n\n\n\n(55\n)\n\n\n232\n\n\n\n99\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nNet income\n\n$\n351\n\n\n$\n475\n\n\n$\n1,289\n\n\n$\n1,240\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nNet income per share:\n\n\n\n\n\n\n\n\n\n\nBasic\n\n$\n1.23\n\n\n$\n1.63\n\n\n$\n4.44\n\n\n$\n4.22\n\n\n\nDiluted\n\n$\n1.22\n\n\n$\n1.62\n\n\n$\n4.43\n\n\n$\n4.19\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nWeighted average shares used in computing net income per share:\n\n\n\n\n\n\n\n\n\n\nBasic\n\n\n286\n\n\n\n292\n\n\n\n290\n\n\n\n294\n\n\n\nDiluted\n\n\n287\n\n\n\n293\n\n\n\n291\n\n\n\n296\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nThe preliminary income statement is estimated based on our current information.\n\n\n\n\n\n\n\n\n\n\n \n\n\nPage 1\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nCONDENSED CONSOLIDATED BALANCE SHEET\n\n\n(In millions, except par value and share data)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOctober 31,\n\nOctober 31,\n\n\n\n\n2024\n\n2023\n\n\nASSETS\n\n\n\n\n\n\n\n\n\n\n \n\n\nCurrent assets:\n\n\n\n\n\n\nCash and cash equivalents\n\n$\n1,329\n\n\n$\n1,590\n\n\n\nAccounts receivable, net\n\n\n1,324\n\n\n\n1,291\n\n\n\nInventory\n\n\n972\n\n\n\n1,031\n\n\n\nOther current assets\n\n\n334\n\n\n\n274\n\n\n\nTotal current assets\n\n\n3,959\n\n\n\n4,186\n\n\n\n\n\n\n\n \n\n\nProperty, plant and equipment, net\n\n\n1,778\n\n\n\n1,270\n\n\n\nGoodwill\n\n\n4,477\n\n\n\n3,960\n\n\n\nOther intangible assets, net\n\n\n547\n\n\n\n475\n\n\n\nLong-term investments\n\n\n175\n\n\n\n164\n\n\n\nOther assets\n\n\n910\n\n\n\n708\n\n\n\nTotal assets\n\n$\n11,846\n\n\n$\n10,763\n\n\n\n\n\n\n\n \n\n\nLIABILITIES AND EQUITY\n\n\n\n\n\n\n\n\n\n\n \n\n\nCurrent liabilities:\n\n\n\n\n\n\nAccounts payable\n\n$\n540\n\n\n$\n418\n\n\n\nEmployee compensation and benefits\n\n\n368\n\n\n\n371\n\n\n\nDeferred revenue\n\n\n544\n\n\n\n505\n\n\n\nShort-term debt\n\n\n45\n\n\n\n—\n\n\n\nOther accrued liabilities\n\n\n398\n\n\n\n309\n\n\n\nTotal current liabilities\n\n\n1,895\n\n\n\n1,603\n\n\n\n\n\n\n\n \n\n\nLong-term debt\n\n\n3,345\n\n\n\n2,735\n\n\n\nRetirement and post-retirement benefits\n\n\n130\n\n\n\n103\n\n\n\nOther long-term liabilities\n\n\n578\n\n\n\n477\n\n\n\nTotal liabilities\n\n\n5,948\n\n\n\n4,918\n\n\n\n\n\n\n\n \n\n\nTotal Equity:\n\n\n\n\n\n\nStockholders' equity:\n\n\n\n\n\n\nPreferred stock; $0.01 par value; 125,000,000 shares authorized; none issued and outstanding\n\n\n—\n\n\n\n—\n\n\n\nCommon stock; $0.01 par value, 2,000,000,000 shares authorized; 285,193,011 shares at October 31, 2024 and 292,123,241 shares at October 31, 2023, issued and outstanding\n\n\n3\n\n\n\n3\n\n\n\nAdditional paid-in-capital\n\n\n5,450\n\n\n\n5,387\n\n\n\nRetained earnings\n\n\n750\n\n\n\n782\n\n\n\nAccumulated other comprehensive loss\n\n\n(305\n)\n\n\n(327\n)\n\n\nTotal stockholders' equity\n\n\n5,898\n\n\n\n5,845\n\n\n\nTotal liabilities and stockholders' equity\n\n$\n11,846\n\n\n$\n10,763\n\n\n\n\n\n\n\n \n\n\nThe preliminary balance sheet is estimated based on our current information.\n\n\n\n\n\n\n \n\n\nPage 2\n\n\n\n\n\n\n \n\n\n\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nCONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS\n\n\n(In millions)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n\n\n\n\n\nYears Ended\n\n\n\n\nOctober 31,\n\nOctober 31,\n\n\n\n\n2024\n\n2023\n\n\nCash flows from operating activities:\n\n\n\n\n\n\nNet income\n\n$\n1,289\n\n\n$\n1,240\n\n\n\n\n\n\n\n \n\n\nAdjustments to reconcile net income to net cash provided by operating activities:\n\n\n\n\n\n\nDepreciation and amortization\n\n\n257\n\n\n\n271\n\n\n\nShare-based compensation\n\n\n129\n\n\n\n111\n\n\n\nDeferred taxes\n\n\n(64\n)\n\n\n(56\n)\n\n\nExcess and obsolete inventory related charges\n\n\n45\n\n\n\n40\n\n\n\nNet (gain) loss on equity securities\n\n\n5\n\n\n\n41\n\n\n\nAsset impairment charges\n\n\n8\n\n\n\n277\n\n\n\nChange in fair value of contingent consideration\n\n\n—\n\n\n\n1\n\n\n\nNet gain on divestiture of business\n\n\n—\n\n\n\n(43\n)\n\n\nOther non-cash (income) expense, net\n\n\n(1\n)\n\n\n6\n\n\n\nChanges in assets and liabilities:\n\n\n\n\n\n\nAccounts receivable, net\n\n\n7\n\n\n\n132\n\n\n\nInventory\n\n\n34\n\n\n\n(33\n)\n\n\nAccounts payable\n\n\n103\n\n\n\n(171\n)\n\n\nEmployee compensation and benefits\n\n\n(12\n)\n\n\n(91\n)\n\n\nOther assets and liabilities\n\n\n(49\n)\n\n\n47\n\n\n\nNet cash provided by operating activities (a)\n\n\n1,751\n\n\n\n1,772\n\n\n\n\n\n\n\n \n\n\nCash flows from investing activities:\n\n\n\n\n\n\nPayments to acquire property, plant and equipment\n\n\n(378\n)\n\n\n(298\n)\n\n\nProceeds from sale of equity securities\n\n\n—\n\n\n\n5\n\n\n\nPayments to acquire equity securities\n\n\n(5\n)\n\n\n(8\n)\n\n\nProceeds from convertible note\n\n\n—\n\n\n\n4\n\n\n\nPayments in exchange for convertible note\n\n\n(13\n)\n\n\n(12\n)\n\n\nProceeds from divestiture of business\n\n\n—\n\n\n\n50\n\n\n\nPayments to acquire businesses and intangible assets, net of cash acquired\n\n\n(862\n)\n\n\n(51\n)\n\n\nNet cash used in investing activities\n\n\n(1,258\n)\n\n\n(310\n)\n\n\n\n\n\n\n \n\n\nCash flows from financing activities:\n\n\n\n\n\n\nProceeds from issuance of common stock under employee stock plans\n\n\n77\n\n\n\n67\n\n\n\nPayment of taxes related to net share settlement of equity awards\n\n\n(30\n)\n\n\n(54\n)\n\n\nPayments for repurchase of common stock\n\n\n(1,150\n)\n\n\n(575\n)\n\n\nPayment of excise taxes related to repurchases of common stock\n\n\n(3\n)\n\n\n—\n\n\n\nPayments of dividends\n\n\n(274\n)\n\n\n(265\n)\n\n\nProceeds from issuance of long-term debt\n\n\n1,197\n\n\n\n—\n\n\n\nRepayments of long-term debt\n\n\n(180\n)\n\n\n—\n\n\n\nPayments of debt issuance costs\n\n\n(9\n)\n\n\n—\n\n\n\nNet proceeds from (repayment of) short-term debt\n\n\n(380\n)\n\n\n(35\n)\n\n\nPayment for contingent consideration\n\n\n—\n\n\n\n(68\n)\n\n\nNet cash used in financing activities\n\n\n(752\n)\n\n\n(930\n)\n\n\n\n\n\n\n \n\n\nEffect of exchange rate movements\n\n\n(2\n)\n\n\n5\n\n\n\n\n\n\n\n \n\n\nNet increase (decrease) in cash, cash equivalents and restricted cash\n\n\n(261\n)\n\n\n537\n\n\n\n\n\n\n\n \n\n\nCash, cash equivalents and restricted cash at beginning of period\n\n\n1,593\n\n\n\n1,056\n\n\n\n\n\n\n\n \n\n\nCash, cash equivalents and restricted cash at end of period\n\n$\n1,332\n\n\n$\n1,593\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nReconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:\n\n\n\n\n\n\n\n\n\n\n \n\n\nCash and cash equivalents\n\n$\n1,329\n\n\n$\n1,590\n\n\n\nRestricted cash, included in other assets\n\n\n3\n\n\n\n3\n\n\n\nTotal cash, cash equivalents and restricted cash\n\n$\n1,332\n\n\n$\n1,593\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n(a) Cash payments included in operating activities:\n\n\n\n\n\n\n\n\n\n\n \n\n\nIncome tax payments, net of refunds received\n\n$\n314\n\n\n$\n199\n\n\n\nInterest payments, net of capitalized interest\n\n$\n80\n\n\n$\n89\n\n\n\n\n\n\n\n \n\n\nThe preliminary cash flow is estimated based on our current information.\n\n\n\n\n\n\n \n\n\nPage 3\n\n\n\n\n\n\n \n\n\n\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nNON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS\n\n\n(In millions, except per share data)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThree Months Ended\n\nYears Ended\n\n\n\n\n\nOctober 31,\n\nOctober 31,\n\n\n\n\n\n2024\n\n2023\n\n2024\n\n2023\n\n\n\n\n\nNet Income\n\nDiluted EPS\n\nNet Income\n\nDiluted EPS\n\nNet Income\n\nDiluted EPS\n\nNet Income\n\nDiluted EPS\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nGAAP net income\n\n$\n351...\n   \n\n$\n1.22\n\n\n$\n475\n\n\n$\n1.62\n\n\n$\n1,289\n\n\n$\n4.43\n\n\n$\n1,240\n\n\n$\n4.19\n\n\n\nNon-GAAP adjustments:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nRestructuring and other related costs\n\n\n5\n\n\n\n0.02\n\n\n\n46\n\n\n\n0.16\n\n\n\n76\n\n\n\n0.26\n\n\n\n46\n\n\n\n0.16\n\n\n\nAsset impairments\n\n\n—\n\n\n\n—\n\n\n\n—\n\n\n\n—\n\n\n\n8\n\n\n\n0.03\n\n\n\n277\n\n\n\n0.94\n\n\n\nIntangible amortization\n\n\n25\n\n\n\n0.09\n\n\n\n27\n\n\n\n0.09\n\n\n\n102\n\n\n\n0.35\n\n\n\n139\n\n\n\n0.47\n\n\n\nTransformational initiatives\n\n\n6\n\n\n\n0.02\n\n\n\n(6\n)\n\n\n(0.02\n)\n\n\n11\n\n\n\n0.04\n\n\n\n25\n\n\n\n0.08\n\n\n\nAcquisition and integration costs\n\n\n7\n\n\n\n0.02\n\n\n\n4\n\n\n\n0.01\n\n\n\n12\n\n\n\n0.04\n\n\n\n16\n\n\n\n0.05\n\n\n\nBusiness exit and divestiture costs (gain)\n\n\n—\n\n\n\n—\n\n\n\n(43\n)\n\n\n(0.15\n)\n\n\n—\n\n\n\n—\n\n\n\n(43\n)\n\n\n(0.15\n)\n\n\nNet loss on equity securities\n\n\n12\n\n\n\n0.04\n\n\n\n27\n\n\n\n0.09\n\n\n\n10\n\n\n\n0.03\n\n\n\n42\n\n\n\n0.14\n\n\n\nPension settlement loss\n\n\n2\n\n\n\n0.01\n\n\n\n4\n\n\n\n0.01\n\n\n\n2\n\n\n\n0.01\n\n\n\n4\n\n\n\n0.01\n\n\n\nChange in fair value of contingent consideration\n\n\n—\n\n\n\n—\n\n\n\n—\n\n\n\n—\n\n\n\n—\n\n\n\n—\n\n\n\n1\n\n\n\n—\n\n\n\nOther\n\n\n13\n\n\n\n0.05\n\n\n\n(11\n)\n\n\n(0.03\n)\n\n\n17\n\n\n\n0.06\n\n\n\n20\n\n\n\n0.07\n\n\n\nAdjustment for taxes (a)\n\n\n(3\n)\n\n\n(0.01\n)\n\n\n(119\n)\n\n\n(0.40\n)\n\n\n12\n\n\n\n0.04\n\n\n\n(158\n)\n\n\n(0.52\n)\n\n\nNon-GAAP net income\n\n$\n418\n\n\n$\n1.46\n\n\n$\n404\n\n\n$\n1.38\n\n\n$\n1,539\n\n\n$\n5.29\n\n\n$\n1,609\n\n\n$\n5.44\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n(a) The adjustment for taxes excludes tax expense (benefits) that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as the realized gain/loss due to sale of a business, windfall benefits on stock compensation, and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017. For the three months ended October 31, 2024, management used a non-GAAP effective tax rate of 11.25%. For the fiscal year ended October 31, 2024, management used a non-GAAP effective tax rate of 12.50%. For the three months and fiscal year ended October 31, 2023, management used a non-GAAP effective tax rate of 13.75%.\n\n\n\n \n\n\nWe provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs (gain), net (gain) loss on equity securities, pension settlement loss and change in fair value of contingent consideration.\n\n\n\n \n\n\nRestructuring and other related costs include incremental expenses incurred in the period associated with restructuring programs, usually aimed at changes in business and/or cost structure. Such costs may include one-time termination benefits, facility-related costs and contract termination fees.\n\n\n\n \n\n\nAsset impairments include assets that have been written down to their fair value.\n\n\n\n \n\n\nTransformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system and human resources and financial systems.\n\n\n\n \n\n\nAcquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, tax, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.\n\n\n\n \n\n\nBusiness exit and divestiture costs (gain) include costs and gain associated with business divestitures.\n\n\n\n \n\n\nNet (gain) loss on equity securities relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities.\n\n\n\n \n\n\nPension settlement loss relates to the relief of the US Retirement Plan pension obligation due to increased lump sum payouts over a specified accounting threshold.\n\n\n\n \n\n\nChange in fair value of contingent consideration represents changes in the fair value estimate of acquisition-related contingent consideration.\n\n\n\n \n\n\nOther includes certain legal costs and settlements, special compliance costs, acceleration of stock-based compensation expense and other miscellaneous adjustments.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nOur management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results \"through the eyes\" of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nOur management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nReaders are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nThe preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nPage 4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nSEGMENT INFORMATION\n\n\n(In millions, except where noted)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n \n\n\nQuarter-over-Quarter\n\n\n\n\n\n\n \n\n\nLife Sciences and Applied Markets Group\n\n\n\n\n\n\n\n\nQ4'24\n\nQ4'23\n\n\nRevenue\n\n$\n833\n\n\n$\n839\n\n\n\nGross Margin, %\n\n\n59.1\n%\n\n\n59.5\n%\n\n\nIncome from Operations\n\n$\n233\n\n\n$\n240\n\n\n\nOperating margin, %\n\n\n28.0\n%\n\n\n28.6\n%\n\n\n\n\n\n\n \n\n\nDiagnostics and Genomics Group\n\n\n\n\n\n\n\n\nQ4'24\n\nQ4'23\n\n\nRevenue\n\n$\n442\n\n\n$\n445\n\n\n\nGross Margin, %\n\n\n51.5\n%\n\n\n53.7\n%\n\n\nIncome from Operations\n\n$\n94\n\n\n$\n101\n\n\n\nOperating margin, %\n\n\n21.2\n%\n\n\n22.7\n%\n\n\n\n\n\n\n \n\n\nAgilent CrossLab Group\n\n\n\n\n\n\n\n\nQ4'24\n\nQ4'23\n\n\nRevenue\n\n$\n426\n\n\n$\n404\n\n\n\nGross Margin, %\n\n\n50.9\n%\n\n\n50.4\n%\n\n\nIncome from Operations\n\n$\n139\n\n\n$\n128\n\n\n\nOperating margin, %\n\n\n32.6\n%\n\n\n31.7\n%\n\n\n\n\n\n\n\n\n\n\n \n\n\nYear-over-Year\n\n\n\n\n\n\n \n\n\nLife Sciences and Applied Markets Group\n\n\n\n\n\n\n\n\nFY24\n\nFY23\n\n\nRevenue\n\n$\n3,215\n\n\n$\n3,510\n\n\n\nGross Margin, %\n\n\n59.7\n%\n\n\n60.3\n%\n\n\nIncome from Operations\n\n$\n877\n\n\n$\n1,049\n\n\n\nOperating margin, %\n\n\n27.3\n%\n\n\n29.9\n%\n\n\n\n\n\n\n \n\n\nDiagnostics and Genomics Group\n\n\n\n\n\n\n\n\nFY24\n\nFY23\n\n\nRevenue\n\n$\n1,651\n\n\n$\n1,755\n\n\n\nGross Margin, %\n\n\n52.4\n%\n\n\n53.4\n%\n\n\nIncome from Operations\n\n$\n320\n\n\n$\n363\n\n\n\nOperating margin, %\n\n\n19.4\n%\n\n\n20.7\n%\n\n\n\n\n\n\n \n\n\nAgilent CrossLab Group\n\n\n\n\n\n\n\n\nFY24\n\nFY23\n\n\nRevenue\n\n$\n1,644\n\n\n$\n1,568\n\n\n\nGross Margin, %\n\n\n50.9\n%\n\n\n49.3\n%\n\n\nIncome from Operations\n\n$\n524\n\n\n$\n463\n\n\n\nOperating margin, %\n\n\n31.9\n%\n\n\n29.5\n%\n\n\n\n\n\n\n\n\n\n\n \n\n\nIncome from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives and acquisition and integration costs.\n\n\n\n\n\n\n \n\n\nReaders are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.\n\n\n\n\n\n\n \n\n\nThe preliminary segment information is estimated based on our current information.\n\n\n\n\n\n\n \n\n\nPage 5\n\n\n\n\n\n\n \n\n\n\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nRECONCILIATIONS OF REVENUE BY SEGMENT\n\n\nEXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)\n\n\n(in millions)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYear-over-Year\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nGAAP\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYear-over-Year\n\n\n\n\n\n\n\n\nGAAP Revenue by Segment\n\nQ4'24\n\nQ4'23\n\n% Change\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nLife Sciences and Applied Markets Group\n\n$\n833\n\n$\n839\n\n(1%)\n\n\n\n\n\n\n\n\nDiagnostics and Genomics Group\n\n\n442\n\n\n445\n\n(1%)\n\n\n\n\n\n\n\n\nAgilent CrossLab Group\n\n\n426\n\n\n404\n\n5%\n\n\n\n\n\n\n\n\nAgilent\n\n$\n1,701\n\n$\n1,688\n\n1%\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nNon-GAAP(excluding Acquisitions & Divestitures)\n\nYear-over-Yearat Constant Currency (a)\n\n\n\n\n\n\n\n\n\n\nYear-over-Year\n\nYear-over-Year\n\nPercentage Point Impact from Currency\n\nCurrent Quarter Currency Impact (b)\n\n\nNon GAAP Revenue by Segment\n\nQ4'24\n\nQ4'23\n\n% Change\n\n% Change\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nLife Sciences and Applied Markets Group\n\n$\n833\n\n$\n839\n\n(1%)\n\n(1%)\n\n—\n\n$\n5\n\n\nDiagnostics and Genomics Group\n\n\n432\n\n\n445\n\n(3%)\n\n(3%)\n\n—\n\n\n3\n\n\nAgilent CrossLab Group\n\n\n426\n\n\n404\n\n5%\n\n5%\n\n—\n\n\n1\n\n\nAgilent (Core)\n\n$\n1,691\n\n$\n1,688\n\n—\n\n—\n\n—\n\n$\n9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nWe compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nThe preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nPage 6\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAGILENT TECHNOLOGIES, INC.\n\n\nRECONCILIATIONS OF REVENUE BY SEGMENT\n\n\nEXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)\n\n\n(in millions)\n\n\n(Unaudited)\n\n\nPRELIMINARY\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nYear-over-Year\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nGAAP\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nYear-over-Year\n\n\n\n\n\n\n\n\nGAAP Revenue by Segment\n\nFY24\n\nFY23\n\n% Change\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nLife Sciences and Applied Markets Group\n\n$\n3,215\n\n$\n3,510\n\n(8%)\n\n\n\n\n\n\n\n\nDiagnostics and Genomics Group\n\n\n1,651\n\n\n1,755\n\n(6%)\n\n\n\n\n\n\n\n\nAgilent CrossLab Group\n\n\n1,644\n\n\n1,568\n\n5%\n\n\n\n\n\n\n\n\nAgilent\n\n$\n6,510\n\n$\n6,833\n\n(5%)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\nNon-GAAP(excluding Acquisitions & Divestitures)\n\nYear-over-Yearat Constant Currency (a)\n\n\n\n\n\n\n\n\n\n\nYear-over-Year\n\nYear-over-Year\n\nPercentage Point Impact from Currency\n\nCurrent Quarter Currency Impact (b)\n\n\nNon GAAP Revenue by Segment\n\nFY24\n\nFY23\n\n% Change\n\n% Change\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nLife Sciences and Applied Markets Group\n\n$\n3,215\n\n$\n3,510\n\n(8%)\n\n(8%)\n\n—\n\n$\n(5)\n\n\nDiagnostics and Genomics Group\n\n\n1,641\n\n\n1,748\n\n(6%)\n\n(6%)\n\n—\n\n\n2\n\n\nAgilent CrossLab Group\n\n\n1,644\n\n\n1,568\n\n5%\n\n5%\n\n—\n\n\n(4)\n\n\nAgilent (Core)\n\n$\n6,500\n\n$\n6,826\n\n(5%)\n\n(5%)\n\n—\n\n$\n(7)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nWe compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n(b) The dollar impact from the current year currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nThe preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nPage 7\n\n\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241125015693/en/\nContacts\nInvestor Contact: Parmeet Ahuja+1 408-345-8948parmeet_ahuja@agilent.com Media Contact: Sarah Litton+1 408-361-0405Sarah.litton@agilent.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486806845"}